To this end, we explored the fractions of various immune cells and cancer neoantigens within cytolytic subgroups in CRC, and predicted which of them would respond better to a hypothetical treatment with CTLA-4 and PD-1 blockers, either alone or in combination. Here, CTLA4 is linked to colorectal carcinoma.